Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06475898 · ClinicalTrials.gov registry record

Longitudinal Endpoint Assessment of Disease Burden in HD

A clinical trial of Huntington Disease, sponsored by Huntington Study Group.

Recruiting
Registry status
600
Enrollment target
1
Study location

NCT06475898 is a study of Huntington Disease that is actively recruiting participants, run by Huntington Study Group. The registered enrollment target is 600 participants, roughly in line with the 618-participant average among 35 other Huntington Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06475898, a study of Huntington Disease, is actively recruiting participants, sponsored by Huntington Study Group.

RECRUITING
Registry status
600 participants
Enrollment target
1
Study location

Study Summary

LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.

Conditions Studied

Study Locations (1)

New York

  • Huntington Study Group - Rochester

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2024-06-25
Est. Completion 2026-12

Sponsor

Huntington Study Group

5 total trials

What the Registry Record Tells You About NCT06475898

The ClinicalTrials.gov registry entry for NCT06475898 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 618-participant average among 35 other Huntington Disease trials with a reported enrollment target. The listed sponsor is Huntington Study Group, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 0 interventions.

NCT06475898 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06475898 about?

NCT06475898 is a clinical study titled "Longitudinal Endpoint Assessment of Disease Burden in HD". LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.

What is the current status of trial NCT06475898?

This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2024-06-25. Estimated completion is 2026-12.

What conditions does trial NCT06475898 study?

This clinical trial studies the following conditions: Huntington Disease.

Who is sponsoring clinical trial NCT06475898?

This trial is sponsored by Huntington Study Group, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06475898 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Huntington Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.